BDNF and osteosarcoma: Methodologically rigorous studies that couple pathway inhibition to predefined immune and clinical endpoints, deploy standardized biospecimen workflows and use harmonized safety reporting are required to determine whether neurotrophin-targeted strategies can remodel the osteosarcoma microenvironment toward durable immune control.